Amgen (AMGN) PT Raised to $260 at Truist Securities

February 4, 2021 6:50 AM EST
Get Alerts AMGN Hot Sheet
Price: $248.95 +0.84%

Rating Summary:
    23 Buy, 15 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 14 | New: 42
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Truist Securities analyst Robyn Karnauskas raised the price target on Amgen (NASDAQ: AMGN) to $260.00 (from $254.00) while maintaining a Hold rating.

The analyst commented, "After 4Q20 EPS call, we took a closer look at AMGN’s profile. Our due-diligence supports our thinking that AMGN is moving into a growth phase & is poised for success; caveat – we don’t know timing. We have greater confidence in volume growth drivers including Repatha, Evenity, Aimovig. We also took a more constructive view on biosimilars to account for pricing dynamics. We see KRAS as key to investor sentiment; we model $1.5B in peak KRAS 3L+ NSCLC sales & need to do more work as our assumptions could be conservative. We updated our model for 4Q20 results; new PT is $260/sh, maintain Hold."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change